bevacizumab off-label retina
Selected indexed studies
- Ranibizumab and bevacizumab for neovascular age-related macular degeneration. (N Engl J Med, 2011) [PMID:21526923]
- Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema. (JAMA Ophthalmol, 2017) [PMID:28152149]
- Real-World Use of Off-Label MVASI in the Treatment of Patients With Neovascular AMD and DME. (Transl Vis Sci Technol, 2024) [PMID:39042047]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ranibizumab and bevacizumab for neovascular age-related macular degeneration. (2011) pubmed
- Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema. (2017) pubmed
- Real-World Use of Off-Label MVASI in the Treatment of Patients With Neovascular AMD and DME. (2024) pubmed
- Future of anti-VEGF: biosimilars and biobetters. (2022) pubmed
- Evaluation of off-label anti-vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey. (2022) pubmed
- Clinical, legal and ethical implications of the intra-ocular (off-label) use of bevacizumab (avastin)--a South African perspective. (2009) pubmed
- Effect of Regulatory Requirement for Patient-Specific Prescriptions for Off-Label Medications on the Use of Intravitreal Bevacizumab. (2016) pubmed
- Anti-vascular endothelial growth factor therapies in ophthalmology. (2025) pubmed
- Off-label use of bevacizumab in retinopathy of prematurity. (2009) pubmed
- Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. (2008) pubmed